Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors

Creative Commons License

Haznedaroglu I. C.

TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.3, pp.247-255, 2013 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.4274/tjh.2013.0108
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.247-255
  • Hacettepe University Affiliated: No


The clinical outcomes and survival of tyrosine kinase inhibitor (TKI)-treated patients with chronic myeloid leukemia (CML) have been significantly improved. The aim of this editorial is to outline critical steps of TKI administration practices during the long-term clinical course of CML based on data obtained from randomized clinical trials and international recommendations. The efficacy of TMI treatment, TM side effects, off-target complications, and long-term morbidities due to both the disease and the drug are common arguments in the management of CML. Complete hematological response, early complete cytogenetic response, faster major molecular response, and deeper, more durable molecular responses (MR4, MR4.5, MR5) are the ultimate goals for TKI-receiving patients with CML.